Pioneering a new field of science and medicine
We’d like to say a big welcome to EnteroBiotix, the latest company to receive funding from a consortium of investors including Gabriel and Equity Gap! EnteroBiotix is patient-centered biotechnology company developing novel medicinal products for use in infections or diseases associated with imbalances of bacteria in the human gastrointestinal tract.
They are building on the clinically proven strategy of faecal microbiota transplantation (FMT). FMT is the process of transferring bacteria from the gut of a healthy donor into the gut of a recipient to restore a healthy balance. Primary focus lies on using the body’s own microorganisms to prevent and treat debilitating infections and diseases.
We wish all the best to the whole team @EnteroBiotix!